HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company,announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology. The patent entitled "Polyoxazoline and compositions comprising the same" (U.S. Patent No. 7,943,141) covers the synthesis
The patent represents years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery. It is the first of many patents that Serina has applied for. "This patent award validates our invention and design of a novel drug delivery platform and allows Serina the opportunity to advance some of its proprietary ideas towards full development and eventually commercialization," said Dr. Michael D. Bentley, Chief Scientific Officer and cofounder of the company. "We are now in a position to build a strong pipeline of polymer therapeutic molecules."
Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.
For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com
Media Contact: Karen Petersen, 256-327-9434
SOURCE Serina Therapeutics, Inc.
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All